News Denmark's Genmab prepares for $500m US IPO Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.
News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News J&J rumoured to be sizing up $12bn Genmab acquisition Speculation mounts that J&J will bid for R&D partner
News Novartis' Arzerra gains CLL approval Development partner Genmab says drug approved in relapsed disease.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
